EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Innovative solid lipid nanoparticle formulations for ocular therapeutics and related patents: A systematic review

Bakr Ahmed, Nitika Saini, Veluchamy A Barathi, Vandana B Patravale, Rohan M Shah, Indu Pal Kaur

Journal of Controlled Release · 2025-09 · 385 · 113992

DOI: 10.1016/j.jconrel.2025.113992 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Controlled Release, 2025-09. Verfasst von Bakr Ahmed und 5 weiteren Autor:innen. Beteiligte Einrichtung: University Instiute of Pharmaceutical Sciences (UIPS), Panjab University, Chandigarh 160014, India. Hauptthemen laut MEDLINE: Nanoparticles, Lipids, Eye Diseases, Drug Delivery Systems. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol-Myers Squibb Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TOPIC: This systematic review explores solid lipid nanoparticles (SLNs) as innovative drug delivery systems for ocular applications. It evaluates their ability to improve bioavailability, sustain drug release, and overcome ocular barriers in treating anterior and posterior segment disorders such as dry eye syndrome, glaucoma, infections, and retinal diseases. Comparisons with traditional delivery systems and other nanoparticle platforms are also addressed. CLINICAL RELEVANCE: Ocular diseases often face challenges in effective drug delivery due to the eye's unique anatomy and physiological barriers. Current treatments, including eye drops and intravitreal injections, are limited by rapid clearance, invasiveness, and systemic side effects. SLNs offer a next-generation alternative, addressing these limitations with enhanced corneal permeability, drug retention, and targeted delivery. METHODS: A comprehensive search was conducted across PubMed, Scopus, Web of Science, and Google Scholar, focusing on studies and patents published from 2010 to 2024. Inclusion criteria targeted original studies using SLNs for ocular applications, excluding studies describing only liposomes and micelles. The PRISMA 2020 guidelines were followed, and data extraction included active pharmaceutical ingredients (APIs), particle size, zeta potential, and therapeutic outcomes. Risk of bias was evaluated using appropriate frameworks. RESULTS: Twenty-eight (28) studies and twenty (20) patents met inclusion criteria, covering SLNs encapsulating APIs such as econazole, atorvastatin, and cannabinoids. Key findings highlighted enhanced bioavailability (up to 12-fold in vitreous humour for atorvastatin-SLNs), sustained release (24-96 h), and improved corneal permeability (up to 287 % higher than controls). Patented formulations incorporated cationic SLNs, PEGylated lipid nanoparticles, and bioactive-loaded SLNs, demonstrating superior stability and therapeutic efficacy. No significant ocular toxicity was observed across in vitro and in vivo studies. CONCLUSION: SLNs represent a transformative approach for ocular drug delivery, combining safety, scalability, commercial viability, and enhanced therapeutic outcomes due to higher permeability and controlled release. However, challenges remain in industrial translation and regulatory approvals. Future research should focus on quality by design (QbD) formulation development; simple, viable, energy-efficient, and preferably organic solvent-free methods of preparation; and leveraging advanced characterization techniques like SAXS and molecular simulations to refine and define SLNs design, molecular structure, and function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesLipidsEye DiseasesDrug Delivery SystemsHumansAnimalsPatents as TopicAdministration, OphthalmicDrug LiberationBiological AvailabilityOphthalmic SolutionsDelayed-Action Preparations

Stichwörter der Autor:innen

Anterior segmentIn vitroOphthalmicPosterior eye diseasesTopical administration

Substanzen

LipidsOphthalmic SolutionsDelayed-Action Preparations

Autor:innen und Institutionen

  • University Instiute of Pharmaceutical Sciences (UIPS), Panjab University, Chandigarh 160014, India.
  • Translational Pre-Clinical Model Platform, Singapore Institute of Eye Research (SERI), Singapore; ACP in Ophthalmology & Visual Sciences, DUKE-NUS Graduate Medical School, Singapore; Department of Ophthalmology, Yong Lo…
  • Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Matunga (E), Mumbai 400 019, Maharashtra, India.
  • Department of Chemistry and Biotechnology, School of Science, Computing and Emerging Technologies, Swinburne University of Technology, Hawthorn, VIC 3122, Australia; Iverson Health Innovation Research Institute, Swinbur…
  • University Instiute of Pharmaceutical Sciences (UIPS), Panjab University, Chandigarh 160014, India. Electronic address: indupalkaur@yahoo.com.

Förderung

  • Bristol-Myers Squibb Company

Zitieren

APA

Ahmed, B., Saini, N., Barathi, V. A., Patravale, V. B., Shah, R. M., & Kaur, I. P. (2025). Innovative solid lipid nanoparticle formulations for ocular therapeutics and related patents: A systematic review. Journal of Controlled Release, 385, 113992. https://doi.org/10.1016/j.jconrel.2025.113992

Vancouver

Ahmed B, Saini N, Barathi VA, Patravale VB, Shah RM, Kaur IP. Innovative solid lipid nanoparticle formulations for ocular therapeutics and related patents: A systematic review. Journal of Controlled Release. 2025;385:113992. doi:10.1016/j.jconrel.2025.113992

BibTeX
@article{Ahmed2025,
  author = {Ahmed, Bakr and Saini, Nitika and Barathi, Veluchamy A and Patravale, Vandana B and Shah, Rohan M and Kaur, Indu Pal},
  title = {Innovative solid lipid nanoparticle formulations for ocular therapeutics and related patents: A systematic review},
  journal = {Journal of Controlled Release},
  year = {2025},
  volume = {385},
  pages = {113992},
  doi = {10.1016/j.jconrel.2025.113992}
}
Kostenlos starten →